In May of 2015 a group of representatives from 14 patient advocacy organizations that support those with risk for cancer and rare cancers convened in Salt Lake City, Utah. Participants discussed the changing need of patients and families with regard to hereditary multi-gene panel testing. The dialog was unbranded in nature with the goal of identifying best practices that could span a range of advocacy organization constituents as the world of genetic testing quickly evolves. This paper summarizes the discussion of panel testing for the benefit of these and other patient advocacy organizations as well as their patient-constituents.
August 2, 2016
Hosted by Kim Thiboldeaux
Guests: Sharyn Lewin, MD, FACS and Barbara Von Bulow, PhD & patient